AbbVie Inc. $ABBV Stock Holdings Trimmed by ZWJ Investment Counsel Inc.

ZWJ Investment Counsel Inc. reduced its position in AbbVie Inc. (NYSE:ABBV) by 2.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 334,519 shares of the company’s stock after selling 6,901 shares during the quarter. AbbVie comprises approximately 2.5% of ZWJ Investment Counsel Inc.’s portfolio, making the stock its 13th biggest position. ZWJ Investment Counsel Inc.’s holdings in AbbVie were worth $87,507,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of ABBV. Mather Group LLC. grew its holdings in shares of AbbVie by 5.6% during the third quarter. Mather Group LLC. now owns 35,883 shares of the company’s stock worth $9,387,000 after buying an additional 1,893 shares during the last quarter. First Pacific Financial raised its stake in AbbVie by 1.1% during the 3rd quarter. First Pacific Financial now owns 28,144 shares of the company’s stock valued at $7,362,000 after acquiring an additional 294 shares during the last quarter. MPS Loria Financial Planners LLC raised its stake in AbbVie by 0.6% during the 3rd quarter. MPS Loria Financial Planners LLC now owns 16,160 shares of the company’s stock valued at $4,227,000 after acquiring an additional 95 shares during the last quarter. Fortitude Family Office LLC raised its stake in AbbVie by 7.7% during the 3rd quarter. Fortitude Family Office LLC now owns 4,552 shares of the company’s stock valued at $1,191,000 after acquiring an additional 327 shares during the last quarter. Finally, Strategy Asset Managers LLC raised its stake in AbbVie by 2.7% during the 3rd quarter. Strategy Asset Managers LLC now owns 2,305 shares of the company’s stock valued at $603,000 after acquiring an additional 61 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by company insiders.

AbbVie Stock Up 3.4%

Shares of NYSE:ABBV opened at $283.58 on Thursday. The company has a market cap of $501.03 billion, a P/E ratio of 80.11, a PEG ratio of 1.25 and a beta of 0.24. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $285.40. The company has a 50-day moving average price of $261.16 and a 200 day moving average price of $238.38.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the company earned $2.97 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts expect that AbbVie Inc. will post 13.95 EPS for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 AFFIRM data showed subcutaneous SKYRIZI improved clinical and endoscopic outcomes in patients with moderately to severely active Crohn’s disease. The results could support regulatory review of a more convenient formulation and strengthen AbbVie’s post-Humira growth outlook. AbbVie Presents New Phase 3 AFFIRM Data
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and maintained a $280 price target, while Erste Group raised its FY2027 EPS estimate to $16.34 from $16.19 and kept a Buy rating. RBC Reaffirms Outperform Rating
• Positive Sentiment: Unusually heavy call-option activity—86,296 calls purchased, roughly 445% above average volume—signals increased bullish speculative interest, although options activity is not a fundamental indicator.
• Positive Sentiment: Healthcare stocks broadly rallied, providing a favorable sector backdrop. Investors are also looking ahead to AbbVie’s October 30 earnings report, with expectations that Rinvoq, Skyrizi and Vraylar will support revenue growth. Lilly, Merck, AbbVie Stocks Surge

Analyst Ratings Changes

Several research analysts have weighed in on ABBV shares. Weiss Ratings upgraded AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. BMO Capital Markets boosted their target price on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. JPMorgan Chase & Co. upped their price target on AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Thursday, October 8th. Barclays upped their price target on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Finally, Oppenheimer increased their price target on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $277.18.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.